NASDAQ:RUBY
Delisted
Rubius Therapeutics Inc. Stock News
$0.0570
+0 (+0%)
At Close: Mar 28, 2024
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
08:00am, Monday, 10'th May 2021
Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM®;Dose Optimization and Enrollment Co
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an en
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
09:52am, Saturday, 20'th Mar 2021
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the bigges
3 Biotech Stocks to Avoid Right Now
06:16am, Thursday, 18'th Mar 2021
Here's why these attention-grabbing stocks could be toxic to your portfolio.
Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options
09:51am, Wednesday, 17'th Mar 2021
Investors need to pay close attention to Rubius Therapeutics (RUBY) stock based on the movements in the options market lately.
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
09:28pm, Tuesday, 16'th Mar 2021
CAMBRIDGE Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
04:32pm, Monday, 15'th Mar 2021
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells
Rubius Therapeutics Stock Trading Higher On Positive Efficacy, Safety RTX-240 Data In Solid Tumor Study
02:06pm, Monday, 15'th Mar 2021
Rubius Therapeutics Inc (NASDAQ: RUBY) stock is trading after reporting initial data from its ongoing Phase 1/2 trial of RTX-240 in patients with advanced solid tumors. Initial efficacy results sh
Why Rubius Therapeutics Stock Is Skyrocketing Today
01:34pm, Monday, 15'th Mar 2021
The company announced positive results from a clinical trial.
RUBY Stock Alert: The Promising Cancer Drug News That Has Rubius Therapeutics Rocketing Today
01:26pm, Monday, 15'th Mar 2021
Rubius Therapeutics (RUBY) stock was flying high on Monday after announcing early results from a clinical trial of its new cancer treatment. The post RUBY Stock Alert: The Promising Cancer Drug News T
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events
RUBY Stock Price Increases Over 40% Pre-Market: Why It Happened
07:17am, Monday, 15'th Mar 2021
The stock price of Rubius Therapeutics Inc (NASDAQ: RUBY) has increased by over 40% pre-market. This is why it happened.
RUBY Stock Price Increased 49.12% After Hours: Why It Happened
08:06am, Sunday, 14'th Mar 2021
The stock price of Rubius Therapeutics (Nasdaq: RUBY) increased by 49.12% on Friday. This is why it happened.
CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an e
